顔用注射剤の世界市場 - 2025年～2033年

顔用注射剤の世界市場は、2024年に131億4,000万米ドルに達し、2032年には276億4,000万米ドルに達すると予測され、予測期間2025年～2033年にはCAGR 9.4％で成長する見込みです。

世界の顔用注射剤市場は、皮膚フィラーや神経毒のような物質の注入を伴う非外科的治療に重点を置く医療美容業界の一分野です。これらの注入剤は主に顔の若返りに使用され、シワを減らし、失われたボリュームを回復し、全体的な肌の質感を改善することで審美性を高めます。

顔用注射剤の種類には、皮膚充填剤と神経毒が含まれます。真皮充填剤は、皮膚の下に注入するジェル状の物質で、ボリュームを与え、しわを滑らかにし、顔の輪郭を強調します。一般的なものとしては、ヒアルロン酸フィラーやカルシウムハイドロキシアパタイトフィラーなどがあります。このカテゴリーの神経毒には、A型ボツリヌス毒素（BOTOXなど）のような製品が含まれ、一時的に筋肉を麻痺させることで、表情によって生じる動的なしわを滑らかにします。

顔用注射剤の主な用途は、特に額、目の周り（カラスの足跡）、口元などの美容的外観の改善です。また、過度の発汗や偏頭痛などの病状を改善するために使用される注射剤もあります。これらの要因が、世界の顔用注射剤市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

非外科的処置に対する需要の高まり

非外科的処置に対する需要の高まりは、世界の顔用注射剤市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。

多くの消費者は、従来の外科的処置と比較して最小限のダウンタイムで効果的な結果を提供するため、注射剤のような非外科的オプションを選択するようになってきています。このような嗜好は、忙しいライフスタイルに合った迅速で便利な治療を求める欲求と一致しています。注射剤の処方と技術における革新は、これらの治療の安全性、有効性、快適性を向上させました。新しい技術は、より正確な注入と、より長持ちする結果を可能にし、非外科的な選択肢を消費者にとってより魅力的なものにしています。

ソーシャルメディアの台頭は、美容治療に対する認識を高め、若々しい外見を維持することへの関心を高めています。インフルエンサーや有名人は、非外科的治療の経験をしばしば共有し、これらの治療を正常化し、他の人々が検討することを奨励しています。外科手術以外の施術に対する需要の増加は、世界の顔用注射剤市場の成長に大きく影響しています。消費者は外見を美しくするために、効果的で、便利で、侵襲性の低い解決策を求め続けているため、この動向は顔用注射剤市場のさらなる革新と拡大を促進すると予想されます。

さらに、業界の主要企業は、この顔用注射剤市場の成長を促進する革新的な製品を発表しています。例えば、2023年8月、Allerganは最新の顔用充填剤Juvederm Voluxを発表しました。Juvedermラインに新たに加わったこの製品は、失われた顔のボリュームを回復させるヒアルロン酸ベースの皮膚充填剤です。Voluxが他の製品と異なるのは、顔の輪郭形成においてより高い性能を発揮するように特別に設計された、そのユニークな粘性です。

Juvederm Voluxは、アゴとアゴのラインを整え、より彫刻的な外観をもたらすようにデザインされています。アラガン社の特許技術であるVYCROSS（ヴァイクロス）を採用しているため、より滑らかなジェル状で皮膚によくなじみます。このフィラーの効果は18～24ヶ月持続するため、これらの部位の美容的向上を求める方には長持ちする選択肢となります。

また、2024年7月、SkinCeuticals社は、神経毒注射の効果からヒントを得て、表情じわを目立たなくするようデザインされた、臨床的に裏付けされたペプチド美容液、P-TIOXを発売しました。この革新的な美容液は、一般的に注射治療で達成される結果を再現・強化することを目的としており、アンチエイジング効果を求める人々に非侵襲的な代替手段を提供します。これらすべての要因が、世界の顔用注射剤市場に需要をもたらしています。

さらに、デジタルツールの統合に対する需要の高まりが、顔用注射剤の世界市場拡大に寄与しています。

副作用と安全性への懸念

副作用と安全性への懸念は、顔用注射剤の世界市場において大きな抑制要因となっています。顔用注射剤は審美性を高めるために広く利用されているが、潜在的な副作用や安全性の問題が消費者の治療意欲を削いでいます。

多くの患者は、注入部位の腫れ、あざ、赤み、痛みなど、注入治療後に一時的な副作用を経験します。これらの反応は一般的に軽度で、数日から数週間で治まります。しかし、特に即時的な審美的改善を求める方にとっては、これらの発生が不満につながる可能性があります。

一般的ではありませんが、感染、血管閉塞、肉芽腫など、より重篤な合併症が顔用注射剤によって生じることがあります。副反応の中には、治療後すぐには現れず、数週間から数ヵ月後に発現するものもあります。例えば、体内に導入された異物に反応して、遅延型過敏反応や慢性炎症が発現することがあります。まれではあるが、注射剤の成分に対するアレルギー反応が起こることもあり、敏感な人ではアナフィラキシーなどの重篤な結果につながることもあります。従って、上記の要因が世界の顔用注射剤市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 非外科的処置の需要増加
  • 抑制要因
    • 副作用と安全性の懸念
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• 皮膚充填剤
  • ヒアルロン酸フィラー（HA）
  • カルシウムヒドロキシアパタイト（CaHA）
  • ポリ-L-乳酸
  • コラーゲン注射剤
  • 脂肪注入
  • ポリメチルメタクリレートマイクロスフィア（PMMA）
• 神経毒
  • ボツリヌス毒素A型（ボトックス）
  • ディスポート
  • ゼオミン

第7章 用途別

• フェイスライン矯正
• 唇の増大
• フェイスリフト
• ニキビ跡の治療
• 脂肪萎縮症の治療
• その他

第8章 エンドユーザー別

• 病院
• 皮膚科クリニック
• メディカルスパ
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• AbbVie.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Galderma
• Merz Pharma
• REVANCE AESTHETICS.
• Sinclair
• Ipsen Pharma.
• Medytox.
• HUGEL.
• Suneva Medical, Inc.（Tiger Aesthetics Medical, LLC.）
• Prollenium Medical Technologies.

第12章 付録

The global facial injectables market reached US$ 13.14 billion in 2024 and is expected to reach US$ 27.64 billion by 2032, growing at a CAGR of 9.4 % during the forecast period 2025-2032.

The global facial injectables market is a segment of the medical aesthetics industry that focuses on non-surgical treatments involving the injection of substances like dermal fillers and neurotoxins. These injectables are primarily used for facial rejuvenation, enhancing aesthetics by reducing wrinkles, restoring lost volume, and improving overall skin texture.

Types of facial injectables include dermal fillers and neurotoxins. Dermal fillers are gel-like substances injected beneath the skin to add volume, smooth out wrinkles, and enhance facial contours. Common types include hyaluronic acid fillers and calcium hydroxylapatite fillers. Neurotoxins in this category include products such as botulinum toxin type A (e.g., BOTOX), which temporarily paralyze muscles to smooth out dynamic wrinkles caused by facial expressions.

The primary use of facial injectables is to improve cosmetic appearance, particularly in areas such as the forehead, around the eyes (crow's feet), and the mouth. Some injectables are also employed for medical conditions, including excessive sweating and migraines. These factors have driven the global facial injectables market expansion.

Market Dynamics: Drivers & Restraints

Growing Demand for Non-Surgical Procedures

The growing demand for non-surgical procedures is significantly driving the growth of the global facial injectables market and is expected to drive throughout the market forecast period.

Many consumers are increasingly opting for non-surgical options like injectables because they offer effective results with minimal downtime compared to traditional surgical procedures. This preference aligns with a desire for quick and convenient treatments that fit into busy lifestyles. Innovations in injectable formulations and techniques have enhanced the safety, efficacy, and comfort of these treatments. New technologies allow for more precise applications and longer-lasting results, making non-surgical options more appealing to consumers.

The rise of social media has heightened awareness of aesthetic treatments, leading to increased interest in maintaining a youthful appearance. Influencers and celebrities often share their experiences with non-surgical procedures, normalizing these treatments and encouraging others to consider them. The increasing demand for non-surgical procedures significantly impacts the growth of the global facial injectables market. As consumers continue to seek effective, convenient, and minimally invasive solutions for enhancing their appearance, this trend is expected to drive further innovations and expansions within the facial injectables market.

Furthermore, key players in the industry have innovative product launches that would drive this facial injectable market growth. For instance, in August 2023, Allergan introduced its latest facial filler, Juvederm Volux. This new addition to the Juvederm line is a hyaluronic acid-based dermal filler to restore lost facial volume. What sets Volux apart from its predecessors is its unique consistency, specifically engineered for enhanced performance in facial contouring.

Juvederm Volux is designed to improve the definition of the chin and jawline, providing a more sculpted appearance. It utilizes Allergan's patented VYCROSS technology, which allows for a smoother gel formulation that integrates well with the skin. This filler's effects can last 18 to 24 months, making it a long-lasting option for those seeking aesthetic enhancements in these areas.

Also, in July 2024, SkinCeuticals launched P-TIOX, a clinically backed peptide serum designed to reduce the appearance of expression wrinkles, drawing inspiration from the effects of neurotoxin injections. This innovative serum aims to replicate and enhance the results typically achieved through injectable treatments, providing a non-invasive alternative for those seeking anti-aging benefits. All these factors demand the global facial injectables market.

Moreover, the rising demand for the growth of integration of digital tools contributes to the global facial injectables market expansion.

Adverse Effects and Safety Concerns

Adverse effects and safety concerns present significant restraints in the global facial injectables market. While these products are widely utilized for aesthetic enhancement, potential side effects and safety issues can deter consumers from pursuing treatment.

Many patients experience temporary side effects following injectable treatments, including swelling, bruising, redness, and pain at the injection site. These reactions are generally mild and resolve within a few days to weeks. However, their occurrence can lead to dissatisfaction, particularly for those seeking immediate aesthetic improvements.

Although less common, more severe complications can arise from facial injectables, including infection, vascular occlusion, and granulomas. Some adverse reactions may not manifest immediately and can occur weeks or months after treatment. For example, delayed hypersensitivity reactions or chronic inflammation may develop in response to the foreign material introduced into the body. While rare, allergic responses to the components of injectables can occur and may lead to severe outcomes such as anaphylaxis in sensitive individuals. Thus, the above factors could be limiting the global facial injectables market's potential growth.

Segment Analysis

The global facial injectables market is segmented based on product type, application, end-user, and region.

Product Type:

The botulinum toxin type A (Botox) segment is expected to dominate the global facial injectables market share

The botulinum toxin type A (Botox) segment holds a major portion of the global facial injectables market share and is expected to continue to hold a significant portion of the global facial injectables market share during the forecast period.

The botulinum toxin type A (Botox) segment is a crucial component of the global facial injectables market, significantly contributing to its growth and popularity. Botulinum toxin type A, commonly referred to as Botox, is a neurotoxin produced by the bacterium Clostridium botulinum. It is primarily utilized in aesthetic medicine to temporarily paralyze specific facial muscles, effectively reducing the appearance of dynamic wrinkles caused by facial expressions.

The main areas treated with Botox include forehead lines, frown lines (glabellar lines), and crow's feet (lines around the eyes). There is a notable increase in consumer interest in aesthetic procedures, particularly among younger demographics who are increasingly seeking preventive treatments. The popularity of Botox as a non-invasive option for wrinkle reduction has played a significant role in its market dominance.

Botox treatments are minimally invasive, requiring little to no downtime, which appeals to consumers looking for quick and effective solutions for facial rejuvenation. This convenience factor has led to higher uptake rates for these treatments. Furthermore, key players in the industry have innovative product launches that would drive this facial injectable market growth. For instance, in September 2024, Allergan Aesthetics announced the launch of BOTOX Cosmetic (onabotulinumtoxinA) for the treatment of masseter muscle prominence (MMP) in China.

This approval by the China National Medical Product Administration (NMPA) marks BOTOX as the first neurotoxin authorized for this indication, addressing a common aesthetic concern where an enlarged masseter muscle can lead to a wider, square jawline. The treatment is designed for adults experiencing marked to very marked MMP and offers a temporary improvement in facial appearance. These factors have solidified the segment's position in the global facial injectables market.

Geographical Analysis

North America is expected to hold a significant position in the global facial injectables market share

North America holds a substantial position in the global facial injectables market and is expected to hold most of the market share.

There is a notable shift towards non-invasive cosmetic treatments, such as facial injectables, as consumers seek effective solutions to enhance their appearance without the risks and recovery times associated with surgical options. This trend is particularly strong among younger demographics who are interested in preventive treatments to maintain a youthful look. As disposable incomes rise, especially in emerging markets, more individuals are willing to invest in aesthetic enhancements. This financial capability allows consumers to prioritize cosmetic procedures, significantly contributing to the overall growth of the facial injectables market.

Innovations in injectable formulations and techniques have improved safety, efficacy, and the longevity of results. New products that provide longer-lasting effects and more natural appearances are attracting a broader consumer base, further driving facial injectables market growth. Beyond cosmetic uses, botulinum toxin type A (Botox) and dermal fillers are increasingly utilized for various medical conditions, including chronic migraines, excessive sweating (hyperhidrosis), and muscle spasms. This versatility enhances their market presence and contributes to overall growth.

The stigma surrounding cosmetic procedures has diminished significantly, leading to greater acceptance of facial injectables among diverse demographics, including men. This cultural shift is expanding the consumer base and increasing demand for these treatments. Social media platforms play a crucial role in promoting aesthetic treatments like Botox and dermal fillers. Influencers and celebrities sharing their experiences with these procedures have normalized cosmetic enhancements, encouraging more individuals to consider them.

Furthermore, key players in the industry have innovative product launches and approvals that would drive this facial injectable market growth. For instance, in July 2024, Merz Aesthetics announced that the U.S. Food and Drug Administration (FDA) has approved XEOMIN (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines, including forehead lines, frown lines, and crow's feet. This new approval expands XEOMIN's indications beyond its initial 2011 approval for treating moderate to severe glabellar lines (frown lines).

Also, in March 2023, in Dallas, Galderma unveiled FACE by Galderma, an innovative aesthetic visualization tool that utilizes augmented reality (AR) to help aesthetic professionals and patients visualize the results of injectable treatments before they commence. This cutting-edge application offers a simulated real-time "before and after" view, allowing patients to see what may be achievable through a personalized treatment plan, thereby addressing concerns about the outcomes of injectable procedures.

Thus, the above factors are consolidating the region's position as a dominant force in the global facial injectables market.

Asia Pacific is growing at the fastest pace in the global facial injectables market share

Asia Pacific holds the fastest pace in the global facial injectables market and is expected to hold most of the market share.

The Asia Pacific facial injectables market is set for significant growth, driven by a variety of key factors. A notable rise in disposable incomes across many Asian nations is enabling consumers to invest more in aesthetic enhancements. As financial resources grow, individuals are increasingly prioritizing cosmetic procedures, which significantly contributes to the growth of the facial injectables market.

There is a growing fascination with both cosmetic surgery and non-surgical aesthetic treatments among consumers in the Asia Pacific region. This interest is particularly strong among millennials and younger demographics who are seeking effective solutions to enhance their appearance. Innovations in injectable formulations and techniques have improved safety, efficacy, and the longevity of results. New products that offer longer-lasting effects and more natural appearances are attracting a broader consumer base, further driving market growth.

Furthermore, key players in the industry product launches that would propel this facial injectables market growth in the region. For instance, in May 2024, Galderma launched its hyaluronic acid injectable filler, Restylane VOLYME, in China, alongside the complementary Shape Up Holistic Individualized Treatment (HIT). This innovative filler is specifically designed to address mid-face aging concerns caused by the loss of structural support, reflecting Galderma's dedication to meeting the needs of both patients and injectors in the region. The introduction of these targeted solutions comes at a time when China's aesthetic medicine market has been rapidly expanding, outpacing global growth rates.

Also, in August 2022, Allergan Aesthetics launched Juvederm VOLUX in India, an injectable implant specifically designed to restore and create facial volume. This product is formulated with 25 mg of hyaluronic acid and 3 mg of lidocaine hydrochloride, making it effective for enhancing the chin and jawline areas. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global facial injectables market.

Competitive Landscape

The major global players in the facial injectables market include AbbVie., Galderma, Merz Pharma, REVANCE AESTHETICS., Sinclair, Ipsen Pharma., Medytox., HUGEL., Suneva Medical, Inc. (Tiger Aesthetics Medical, LLC.), and Prollenium Medical Technologies. Among others.

Key Developments

• In September 2024, Obagi Medical, launched two revolutionary skincare products: ELASTIDERM Lift Up & Sculpt Facial Moisturizer and ELASTIDERM(R) Advanced Filler Concentrate. These new offerings promise transformative results by utilizing cutting-edge technology and advanced formulations to improve skin appearance and texture.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global facial injectables market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by Material
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Demand for Non-Surgical Procedures
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects and Safety Concerns
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Dermal Fillers*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Hyaluronic Acid Fillers (HA)
  • 6.2.4. Calcium Hydroxylapatite (CaHA)
  • 6.2.5. Poly-L-lactic Acid
  • 6.2.6. Collagen Injectables
  • 6.2.7. Fat Injection
  • 6.2.8. Polymethyl Methacrylate Microspheres (PMMA)
• 6.3. Neurotoxins
  • 6.3.1. Botulinum Toxin Type A (Botox)
  • 6.3.2. Dysport
  • 6.3.3. Xeomin

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Facial Line Correction*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Lip Augmentation
• 7.4. Face Lift
• 7.5. Acne Scar Treatment
• 7.6. Lipoatrophy Treatment
• 7.7. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Dermatology Clinics
• 8.4. MedSpas
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. AbbVie. *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Galderma
• 11.3. Merz Pharma
• 11.4. REVANCE AESTHETICS.
• 11.5. Sinclair
• 11.6. Ipsen Pharma.
• 11.7. Medytox.
• 11.8. HUGEL.
• 11.9. Suneva Medical, Inc. (Tiger Aesthetics Medical, LLC.)
• 11.10. Prollenium Medical Technologies.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us